Atorvastatin · larger labeled portfolio than Sofosbuvir/Velpatasvir
SPL labels Sofosbuvir/Velpatasvir + Atorvastatin as minor; Sofosbuvir/Velpatasvir 20 / Atorvastatin 25 in that band.
Mechanism on file: This hepatitis C medicine can increase the amount of atorvastatin in your body, making side effects more likely.
FDA SPL severity: Minor
Sofosbuvir/Velpatasvir + Atorvastatin · SPL mechanism field
This hepatitis C medicine can increase the amount of atorvastatin in your body, making side effects more likely.
Minor band excerpt · Sofosbuvir/Velpatasvir with Atorvastatin
atorvastatin fluvastatin lovastatin simvastatin ↑ atorvastatin ↑ fluvastatin ↑ lovastatin ↑ simvastatin Coadministration with VOSEVI may increase the concentrations of atorvastatin, fluvastatin, lovastatin, and simvastatin.
Sofosbuvir/Velpatasvir · 20 minor + 33 total pairs
- Bictegravir/Emtricitabine/Tenofovir minor
- Dabigatran minor
- Darunavir minor
- Digoxin minor
Atorvastatin · 36 SPL pairs (broader portfolio than Sofosbuvir/Velpatasvir)
- Amiodarone minor
- Bazedoxifene/Conjugated Estrogens minor
- Digoxin minor
- Drospirenone/Ethinyl Estradiol minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.